title: First Axl inhibitor enters clinical trials.
authors.forename: Cormac
authors.initials: C
authors.lastname: Sheridan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents; D035843:Biomedical Research; D004345:Drug Industry; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D000076202:c-Mer Tyrosine Kinase; D000094963:Axl Receptor Tyrosine Kinase
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; C097072:MERTK protein, human; D020794:Receptor Protein-Tyrosine Kinases; D000076202:c-Mer Tyrosine Kinase; D000094963:Axl Receptor Tyrosine Kinase
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9
references.pmid: 20080645
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):130-8
references.pmid: 18172262
references.citation: Cancer Res. 2010 Feb 15;70(4):1544-54
references.pmid: 20145120
references.citation: Cell. 2007 Dec 14;131(6):1124-36
references.pmid: 18083102
references.citation: Nat Genet. 2012 Jul 01;44(8):852-60
references.pmid: 22751098
references.citation: Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13091-6
references.pmid: 23878224
references.citation: Biochem Biophys Res Commun. 2013 Jun 7;435(3):493-500
references.pmid: 23684620